The Advisory Committee on Immunization Practices (ACIP)

The Advisory Committee on Immunization Practices (ACIP) is a committee of nonfederal experts who make recommendations to the Department of Health and Human Services (HHS) regarding the use of vaccines and related agents for the control of vaccine-preventable disease in the U.S. civilian population. As a critical function, ACIP recommendations inform the Centers for Disease Control and Prevention’s (CDC’s) annual immunization schedules of recommended vaccines for both children and adolescents (18 years of age and younger) and adults (19 years of age and older). ACIP may also make recommendations regarding nonroutine vaccines, including for use in emergency situations such as the Coronavirus Disease 2019 (COVID-19) pandemic or the mpox outbreak.

ACIP Establishment and History
The Advisory Committee on Immunization Practices was established by the Surgeon General in March 1964 under general authority provided by Public Health Service Act (PHSA) in Section 222 (42 U.S.C. §217a). ACIP was established to provide ongoing expert advice on federal immunization policy in response to expanded federal immunization programs and the licensure of several new vaccines. In 1972, ACIP was designated a federal advisory committee under the Federal Advisory Committee Act (FACA, P.L. 92-463; 5 U.S.C. Appendix).

Overview
Today, ACIP provides recommendations to CDC, the lead federal agency for domestic public health and immunization programs. The committee remains authorized under general authority, and its structure and functions are governed by its official charter per FACA requirements. However, under several federal laws, ACIP and its recommendations play a role in defining the relevant statutory requirements (as explained below in the “Statutory Roles” section.)

Structure and Membership
Per its charter, ACIP currently consists of 15 voting members who have clinical, scientific, and public health expertise in immunization. One lay member is a consumer representative with knowledge about social and community aspects of immunization programs. In addition, several federal health officials and representatives from national health organizations (e.g., American Academy of Pediatrics) serve as nonvoting representatives.

Voting members are appointed by the HHS Secretary and serve overlapping four-year terms. Anyone can apply to become a member, with selection based on meeting certain qualifications. Per HHS policy, the department seeks to balance committee membership in terms of points of view, professional training, and personal backgrounds.

ACIP holds full-committee public meetings at least three times per year to review evidence and vote on new recommendations. Outside these meetings, ACIP members serve on work groups to review evidence regarding specific vaccines on an ongoing basis. ACIP work groups can solicit and consider public comments. ACIP work groups present evidence reviews and draft recommendations to the full committee for consideration. Final recommendations must receive a vote from a majority of the committee.

Recommendation Process and Criteria
ACIP recommendations regarding vaccines and their use are related to, but distinct from, the U.S. Food and Drug Administration’s (FDA’s) licensure or authorization of vaccines. Per its charter, ACIP recommendations are focused on the control of vaccine-preventable diseases, whereas FDA generally focuses its review on the safety and efficacy of vaccines and the processes used to manufacture them. ACIP typically makes its recommendations after FDA has approved or authorized a new vaccine (or an existing vaccine for a new indication). Per a requirement added by the 21st Century Cures Act of 2016 (Cures Act; P.L. 114-255, §309), ACIP must consider any newly licensed vaccine (or new indication) at the committee’s next regularly scheduled meeting. In addition, ACIP can make recommendations regarding other medical products (e.g., antimicrobial therapy) shown to be effective against a disease for which a vaccine is available.

In its review and recommendation process, ACIP weighs whether the benefits of recommending a certain vaccine for a certain population—including the impact of such a recommendation on disease transmission or reduction in disease, hospitalizations, and deaths—outweigh any possible harms at an individual or population level. Harms could include, for example, considerations around vaccine safety (individual level) or disease distribution within the population (population level). ACIP also considers the potential public health importance, quality of the evidence used, implementation considerations, equity, and values and preferences of the people affected. In a few cases, ACIP’s recommendations have differed from FDA-approved indications for use, resulting in recommendations for “off-label” use of vaccines.

ACIP recommendations can be informed by the FDA-approved vaccine label, published and unpublished clinical data from the vaccine manufacturer, and other independent studies. ACIP follows the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) approach for determining the quality and strength of evidence for recommendations. The GRADE approach is commonly used for formulating health recommendations in the United States and around the world.
Recommendation Types
ACIP structures its recommendations to inform clinical and public health practice. ACIP recommendations include (1) the age and other population groups (e.g., by sex, occupation) recommended to receive that vaccine; (2) the recommended age or frequency to receive each dose and the interval between doses (for multidose vaccines); and (3) any precautions and contraindications. Some ACIP recommendations are made for all people in a certain age group, whereas others are risk-based or targeted to specific patients in specific circumstances (e.g., travel vaccines). ACIP recommendations are also made in two categories:

- **Standard Recommendation:** Vaccination recommendations are made for all people in an age or risk-based group.
- **Shared Clinical Decisionmaking:** Vaccination should be based on shared clinical decisionmaking between providers and patients.

ACIP may revise its previous recommendations based on new evidence or new circumstances, such as disease outbreaks or vaccine shortages. Some ACIP recommendations are issued as “interim” recommendations, meaning that they may be subject to change.

Agency Adoption of Recommendations
ACIP’s recommendations are not automatically adopted as official federal recommendations. CDC reviews and decides whether to formally adopt ACIP’s recommendations. Official recommendations are published in the CDC Morbidity and Mortality Weekly Report. In emergency situations, CDC may issue a vaccine recommendation without consultation from ACIP.

Immunization Schedules
ACIP votes on the overall child and adult immunization schedules once per year, which reflect recommendations already made by ACIP that year. The immunization schedules provide structured reference for clinicians on the recommended ages and dosing schedules for vaccines, along with any contraindications or precautions. The current immunization schedules adopted by CDC represent a harmonized set of recommendations made by ACIP and other medical associations, such as the American Academy of Pediatrics and American Academy of Family Physicians. Vaccines listed on the immunization schedules are considered recommended for routine use.

Emergency Recommendations
ACIP can make recommendations for the use of vaccines in emergency situations, such as the COVID-19 pandemic. As required by the Cures Act (P.L. 114-255, §3091), ACIP is to make recommendations “in a timely manner, as appropriate” for vaccines that could be used in a public health emergency. During the pandemic, ACIP made two types of recommendations. First, ACIP made recommendations regarding the use of vaccines and dosing by age group following FDA authorizations or approvals. Second, in the early stages of the vaccine distribution program, ACIP made recommendations regarding the allocation of vaccines, specifically priority groups to receive the limited supply of vaccines. For example, in December 2020, ACIP recommended that health care personnel and residents of long-term care facilities be the first to receive COVID-19 vaccines. Again, these were recommendations; some states set their own priority groups.

Statutory Roles
Some laws, such as the Cures Act (P.L. 114-255), have addressed ACIP and its recommendation process. In addition, ACIP and its recommendations play a role in defining some statutory requirements, including the following:

- **Vaccines for Children (VFC):** Under Social Security Act (SSA) Section 1928 (42 U.S.C. §1396s) ACIP is tasked with developing the list of vaccines covered under the VFC program, which provides vaccines at no cost to eligible children.
- **Health care coverage:** Several laws reference ACIP recommendations in the context of health care coverage requirements, including for private health insurance (PHSA Section 2713; 42 U.S.C. §300gg–13), and more recently for Medicare Part D, Medicaid, and the State Children’s Health Insurance Coverage Program as added by P.L. 117-169. See CRS Report R47396, *Health Care Provisions of the Budget Reconciliation Measure P.L. 117-169*.

ACIP recommendations may also play a role in determining vaccines covered by the Vaccine Injury Compensation Program (VICP), a no-fault system to compensate individuals injured as a result of a covered vaccine. Under PHSA Section 2114 (42 U.S.C. §300aa-14), vaccines recommended by CDC for routine administration to children and pregnant women must be added to the table of covered vaccines under VICP. ACIP is not explicitly mentioned, but in practice, ACIP informs CDC recommendations. However, VICP cannot provide compensation for a new type of vaccine until that vaccine type is added to the list of taxable vaccines under 26 U.S.C. §4131. In other words, a CDC recommendation alone does guarantee compensation under VICP for a certain vaccine.

Immunization Requirements
ACIP recommendations are simply that: recommendations. They do not constitute immunization requirements. Immunization requirements are primarily imposed by state law on specified populations, such as students. There are some federal requirements for limited populations, such as for military personnel and immigrants, or in limited context, such as for staff of Medicare and Medicaid-participating entities in response to the COVID-19 pandemic.

With respect to state immunization requirements, some state laws and regulations direct state health agencies to consider ACIP recommendations when determining school vaccination requirements. No state, however, automatically incorporates ACIP-recommended vaccines into their immunization requirements. Several states expressly ban student COVID-19 vaccine mandates.

Kavya Sekar, Analyst in Health Policy
Disclaimer

This document was prepared by the Congressional Research Service (CRS). CRS serves as nonpartisan shared staff to congressional committees and Members of Congress. It operates solely at the behest of and under the direction of Congress. Information in a CRS Report should not be relied upon for purposes other than public understanding of information that has been provided by CRS to Members of Congress in connection with CRS’s institutional role. CRS Reports, as a work of the United States Government, are not subject to copyright protection in the United States. Any CRS Report may be reproduced and distributed in its entirety without permission from CRS. However, as a CRS Report may include copyrighted images or material from a third party, you may need to obtain the permission of the copyright holder if you wish to copy or otherwise use copyrighted material.